Nuevolution: Presentation of Preclinical Data on its BET BD1 Program at Discovery on Target 2016

NuEvolution logo new

Stockholm, Sweden,  September 16, 2016 / B3C newswire / -- Nuevolution AB (publ) (NUE.ST) will present preclinical data from its BET BD1 program at Discovery on Target 2016 (DoT 2016) in Boston, MA, USA, on 20 and 22 September.

The oral presentation by Jimmi G. Seitzberg, Project Manager, Nuevolution, is titled “NUE7770 - A BET-BD1 selective chemical probe with potent cellular and in vivo anti-inflammatory activity”. The poster will be available for attendants of the symposium on Tuesday 20 September and is to be made available on on the same day. On Thursday 22 September, Mr. Seitzberg will give a 20-minute oral presentation of the data.

NUE7770 is currently being tested in mouse models of Systemic Lupus Erythematosus (SLE) and Idiopathic Lung Fibrosis (IPF), severe inflammatory diseases.

About bromodomain proteins
BET bromodomain proteins play an important role in regulation of gene expression, which thereby affect inflammatory responses and the ability of cancer cells to sustain growth and survive. The human proteome comprises 46 bromodomain-containing proteins, many of which are thought to be involved in cancer, inflammation and cardiovascular disease.         

About Nuevolution
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was sent for publication on Friday 16 September 2016, 13:00 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ).


Thomas Franch, CSO
+45 7020 0987
This email address is being protected from spambots. You need JavaScript enabled to view it.

Henrik D. Simonsen, CFO
+45 3913 0947
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.